American Association for Cancer Research (AACR) Annual Meeting 2019

View All

American Association for Cancer Research (AACR) Annual Meeting 2019

April 04, 2019

Share on:

Biocytogen Highlights

10 Posters highlight new IO targets (e.g. CTLA-4, OX40, CD3e), preclinical services, PK/PD studies, and antibody screening platform will be presented at AACR.

Time	Abstract Full Name	Abstract #	Board #	Category
Apr 1 8AM - 12PM	Anti-SIRPα antibodies as a potential weapon for cancer immunotherapy via accelerated screening in humanized mouse models	1212	9	Experimental and Molecular Therapeutics
Apr 1 8AM - 12PM	Novel hCD3e mouse models for preclinical pharmacology study of therapeutic bispecific antibody	1469	21	Immunology
Apr 1 8AM - 12PM	The human immune reconstituted B-NDG mouse models are perfect tools for CART efficacy evaluation and therapeutic antibody preclinical pharmacology study	1052	3	Tumor Biology
Apr 1 1PM - 5PM	In vivo drug screening platform accelerated 4-1BB agonistic antibody development	2379	3	Immunology
Apr 1 1PM - 5PM	Rapid screening of anti-OX40 antibodies for cancer immunotherapy	1924	8	Tumor Biology
Apr 2 8AM - 12PM	Novel anti-CD40 antibodies demonstrate anti-tumor activity in humanized mouse models	3241	21	Immunology
Apr 2 8AM - 12PM	Novel CTLA-4 antibodies of potent antitumor activity were verified in humanized mouse models	3233	13	Immunology
Apr 2 8AM - 12PM	In vivo efficacy and safety evaluation of anti-human PD-1 and CD40 mAbs using double humanized PD-1/CD40 mouse model	3219	29	Immunology
Apr 2 1PM - 5PM	PK-PD Modelling of An Anti-CTLA-4 Antibody on Immune Checkpoint Humanized Mice	3906	26	Experimental and Molecular Therapeutics
Apr 3 8AM - 12PM	Using humanized B-hSIRPa/hCD47 mouse model to evaluate the efficacy and toxicity of CD47 and SIRPa antibodies	4975	28	Immunology

Learn about Biocytogen’s enhanced capabilities: One-stop solution from concept to IND. Extensive experience in:

Humanized immune checkpoint mouse models for Preclinical efficacy and pharmacology studies

Immune-deficient mice (B-NDG) for PDX, CDX and immune system reconstitution studies

Our integrated antibody discovery platform accelerates drug discovery and development

Customized genetically modified animal and cell models using our innovative CRISPR-based Extreme Genome Editing (EGE) technology, which increases homologous recombination (HR) efficiency by 20 times.

Our senior scientists and the leadership team will be available at the Meeting to discuss research strategies, collaboration, and business development opportunities.

Come to Booth 1613 to win Starbucks and Amazon gift cards! You can schedule a face-to-face meeting HERE！

Follow our LinkedIn news to keep you updated or email us at [email protected]